reason report
launch
bottom line publish first analysi physician note
sourc electron medic record compris
activ physician us ahead nr earn order
gaug prescript trend vyndaqel/vyndamax tafamidi
track chang diagnosi rate attr-amyloidosi project
tafamidi sale use natur languag process
nlp track tafamidi prescript attr-amyloidosi diagnos
data normal sourc data patient number
disclos pfe earn call link sourc data
impli increas tafamidi prescript
minim discontinu suggest rapid uptak project on-going
ramp convers patient commerci drug estim
report sale well us
consensu estim analysi vs consensu
broadli line previou survey work
data support script trend medacorp
fda approv tafamidi ttr cardiomyopathi attr-
cm steadili increas script patient number support strong
launch larg opportun tafamidi inde result
medacorp ttr amyloidosi survey show physician
believ tafamidi hold command share attr-cm mix
phenotyp patient compet patisiran lead share
patient project patient
sensit analysi around gross net discount percent patient
convert commerci program impli upsid scenario
us tafamidi revenu
tafamidi pois decis beat posit read-through
stock univers ahead earn see
earn preview note ttr model align tafamidi
number project analysi lower us
estim ww tafamidi
estim tafamidi rel
undermodel analyst ww estim well
report consensu svbl vs consensu
analysi valid posit outlook rapid tafamidi
launch view net posit op /eidx op
small neg mp inotersen fall behind
approv ttr agent mix neg mp patisiran
remain distinct second cardiomyopathi remain key agent
pleas refer page import disclosur price chart analyst certif
weekli script medacorp survey result support steadi tafamidi uptak
tafamidi approv earli may weekli script continu demonstr rapid drug launch
uptak increas scripts/week scripts/week
cumul increas script data line
patient number disclos pfe earn call link along recent result
publish medacorp ttr amyloidosi survey ttr-treat us physician link
respond expect increas new patient start next month
exhibit weekli script data suggest rapid tafamidi uptak adopt
tafamidi uptak increas attr-amyloidosi diagnos reflect data
use data svb leerink puls product use data sourc
realhealthdatasm rewrdtm databas order monitor patient flow attr-
amyloidosi collect daili data follow tafamidi approv earli may
normal data end report attr-amyloidosi patient number
tafamidi revenu pfe earn call first publish analysi
record data track impli prescript trend approv ttr agent onpattro
patisiran tegsedi inotersen analysi
observ increas impli tafamidi prescript minim
discontinu concurr data demonstr increas attr-amyloidosi
diagnos extrapol impli growth patient patient
broadli line medacorp kol feedback consist suggest
avail tafamidi catalyst increas non-invas attr-cm screen
cardiologist ratio tafamidi prescript attr-amyloidosi diagnos increas
last quarter exhibit altogeth data suggest
increasingli patient attr-amyloidosi prescrib tafamidi
seen earli return initi patient identif advocaci effort build attr-
exhibit data suggest increas diagnosi tafamidi prescript rate
svb leerink research data puls data sourc realhealthdatasm
increas convers patient pool commerci drug drive tafamidi
sale disclos patient prescrib tafamidi compris
patient non-eap program along patient expand access program
eap patient report tafamidi us sale realiz
patient inclus non-eap patient treat along
eap program move forward immedi sourc commerci revenu
patient diagnos attr-cm prescrib tafamidi
non-eap patient prescrib tafamidi along patient eap
program also prescrib even without new patient diagnos
avail pool patient readi transit commerci program exhibit
exhibit patient backlog multipl sourc patient flow commerci tafamidi
use combin data medacorp survey result link project
tafamidi patient number quarterli revenu estim disclos
patient prescrib tafamidi sourc data impli averag
increas patient per week infer treat patient end
project forward assum weekli growth tafamidi prescript
therebi indic patient prescrib tafamidi year-end exhibit estim
increas prescrib patient year-end drawn multipl
commerci sourc includ pool non-eap attr-cm patient
prescrib tafamidi well new pool patient diagnos attr-amyloidosi
data impli increas attr-amyloidosi diagnos patient per quarter exhibit
exhibit estim increas flow patient commerci drug
svb leerink research data puls data sourc realhealthdatasm
project data forward impli sale patient
prescrib tafamidi convert commerci impli convers rate
commerci drug physician ttr medacorp survey august suggest
patient prescrib tafamidi receiv drug
reimburs thu impli weekli ramp patient
transit commerci drug point toward cumul increas
commerci patient end project forward assum weekli
increas convers commerci impli convers commerci rate
prescrib patient ye altogeth estim new commerci tafamidi
patient cumul total patient treat drug
exhibit impli us tafamidi revenu exhibit
svb leerink research data puls data sourc realhealthdatasm
sensit analysi suggest top end estim floor us
sale previous announc list price tafamidi assum gross
net discount impli monthli net price assumpt may
conserv mid-year launch find mani medicar patient alreadi donut
hole sensit us tafamidi sale around gross net discount weekli
increas patient share commerci drug implic baselin assumpt
latter weekli illustr exhibit altogeth sensit analysi impli
top end us sale floor exhibit
svb leerink research data puls data sourc realhealthdatasm
gross net discountgross net convers commerci drug weekli biopharma
mani foroohar certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori inc
leerink place market perform rate octob
creat bluematrix
price target base discount cash flow methodolog forecast sale
onpattro basi probability-weight scenario analysi risk-adjust sale pipelin
agent givosiran lumasiran risk-adjust royalti partner program fitusiran inclisiran explicitli
model expens result cash flow assum discount rate consist compani
coverag univers revenu gener approv product wholli own independ
commerci least one end-market termin growth rate addit factor alni net cash
balanc valuat
risk valuat
risk view outlook valuat alnylam includ major chang price reimburs
coverag unit state europ rare diseas drug onpattro compani key pipelin
drug givosiran lumasiran forecast onpattro also subject
risk better-than-expect market share inotersen tafamidi unmodel competit entrant use
disrupt technolog gene edit risk alnylam includ clinic regulatori disappoint
pipelin excess factor probabl adjust addit onpattro sale profit
fail match estim dilut financ beyond forecast model may requir order support
futur commerci oper clinic develop pipelin agent
rate price target histori inc
creat bluematrix
price target base discount cash flow methodolog forecast cash flow
assign termin growth rate discount rate factor bbio net cash balanc
project sale ttr amyloidosi basi probability-weight scenario analysi sale
infigratinib pipelin asset risk-adjust basi
risk valuat
risk view outlook valuat bridgebio includ major chang price reimburs
coverag unit state europ would affect key pipelin drug infigratinib eido qed
therapeut two largest valuing-driv subsidiari compani potenti clinic setback
commerci under-perform infigratinib would disproportion decreas valuat estim
addit subsidiari compani integr bridgebio manag complex may grow time
increas risk addit new unmodel competit entrant could potenti compet market share
bbio development candid reduc futur cash flow project
rate price target histori inc
creat bluematrix
month price target base dcf methodolog forecast risk-adjust sale
explicitli model expens result cash flow assum discount rate consist
clinical-stag pre-revenu compani coverag univers termin growth rate addit
includ eidx net cash balanc valuat
risk valuat
risk view outlook valuat eido includ major chang price reimburs
coverag unit state europ rare diseas drug forecast also subject
risk better-than-expect market share perform tafamidi unmodel competit entrant use
disrupt technolog gene edit greater-than-expect success penetr
wtttr and/or ttr-cm segment risk eido includ unexpect off-target safeti risk
regulatori requir approv requir greater-than-expect pivot studi durat sampl size
unfavor statist analysi method case eido may requir dilut financ forecast
rate price target histori inc
leerink place market perform rate predecessor organ april becam decemb
creat bluematrix
month price target share base discount cash flow methodolog forecast sale
tegsedi royalti spinraza on-going revenu risk-adjust sale royalti key pipelin agent
partner program explicitli model expens result cash flow assum
discount rate consist compani coverag univers revenu gener approv product
wholly-own independ commerci least one end-market termin growth rate
addit factor ionss net cash balanc valuat
risk valuat
risk view outlook valuat includ major chang price reimburs coverag
unit state europ rare diseas drug tegsedi spinraza compani key pipelin
drug forecast tegsedi also subject risk better-than-expect market share patisiran tafamidi
unmodel competit entrant use disrupt technolog gene edit risk
includ clinic regulatori disappoint pipelin excess factor probabl
adjust addit sale profit fail match estim ioni unabl continu secur
cash flow gener research develop partnership line forecast dilut financ may
requir order support futur commerci oper clinic develop pipelin agent
rate price target histori pfizer inc
leerink place market perform rate novemb
creat bluematrix
suspend coverag share longer put forth statement valuat
risk valuat
sinc suspend coverag longer put forth risk valuat
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
